Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Benznidazol and Triazol REsearch group for Nanomedicine and Innovation on Chagas diseasE (BERENICE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Spain,Spain,Brazil,Argentina,France,Portugal
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-09-01
End date: 2018-08-31
Duration (months): 72.0
Total project cost (EUR): 3900977.04
EU funding (EUR): 2998217.0
Participants: 11
Project status: CLOSED

The BERENICE consortium is aiming at providing a new and cost-effective solution to a better treatment for Chagas chronic patients. Please see its objectives below : Main objective • Obtain a more effective, better tolerated and cheaper formulation of a drug with trypanocidal activity to cure Chagas disease Specific Objectives • Obtain results of pharmacokinetics of new formulations • Assess trypanocidal activity of new formulations in vitro and in animal model • Involve partners, research and industry in endemic countries to promote technology transfer and promote in-site solutions at cheaper cost. The foreseen results of this project would have firstly an impact on the better comprehension and control of the SUVs behavior as drug delivery nanodevices for the specific APIs to be conjugated. If this conjugation is successful, further impacts are expected dealing with technology transfer issues, such as scale-up of the corresponding SUVs preparation methodology and its implementation at industrial scale. Apart from including stong participation from endemic countries's institutions, the consortium also involves private companies, thus enabling the participation of all the key actors of the chain to confront and control better Chagas disease. The innovative approach, through the new developed nano- and microparticles based formulations will have an important impact on the safety of the medicament since the therapeutic efficacy will increase and consequently the doses needed and the incidences caused by adverse effects will be reduced.

Keywords: chagas,nanomedecine,benznidazol,triazol
User-driven Development of Statistical Methods for Experimental Planning, Data Gathering, and Integrative Analysis of Next Generation Sequencing, Proteomics and Metabolomics data (STATEGRA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Spain,Denmark,Germany,Sweden,United Kingdom,Greece,Spain,Netherlands,Netherlands,Germany,United States
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-10-01
End date: 2015-09-30
Duration (months): 36.0
Total project cost (EUR): 7856483.49
EU funding (EUR): 5998574.53
Participants: 11
Project status: CLOSED

Users of NGS technologies, producing large and numerous distinct types of omics data, demands statistical methods to combat data and knowledge fragmentation and inappropriate procedures for data analysis. Yet, the current a gap between the available tools for analysis of a single omics data-type versus the requirement of biomedical scientists to understand the integrated results derived from several omics data-types, threatens to further increase due to the accelerated capacity of data production. STATegra will therefore improve and develop new statistical methods enabling accurate collection and integration of –omics data while providing user-friendly packaging of STATegra tools targeting biomedical scientists. To close the gap between the present sub-optimal utilization of –omics data and the power of statistics, STATegra develops statistical methods targeting efficient experimental design, data gathering, missing data, noisy data, current knowledge, meta-analysis and integrative data analysis. Importantly, STATegra facilitates understanding and use of –omics data by forcing abstract concepts including knowledge, design, dirty data, visualization, causality and integration to be embedded in a real yet prototypical biomedical context. STATegra is positioned to ensure that the collective output of the statistical STATegra methods is relevant and subject to “statistical and experimental” validation and iteration. STATegra mimics a user-driven IT development strategy, by involving real biomedical users as beta-testers. To deliver beyond current exploratory tools, our consortium accumulates the necessary strong statistical, technological, and molecular expertise. The strong lead by research intensive SMEs, with proven track-record in software deployment, translates STATegra to a wide existing community base. STATegra accelerates the production of relevant statistical tools impacting a broad community of biomedical scientists in research, industry, and healthcare.

Keywords: statistical methods,integrative analysis,data integration,data management,visualization,experimental design,omics,next generation sequencing,metabolomics,proteomics,software engineering
Social Innovations Promoting Active and Healthy Ageing (INNOVAGE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: United Kingdom,Sweden,Germany,United Kingdom,Italy,Belgium,Latvia,Luxembourg
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-12-01
End date: 2015-11-30
Duration (months): 36.0
Total project cost (EUR): 3720773.8
EU funding (EUR): 2989877.0
Participants: 9
Project status: CLOSED

INNOVAGE is an ambitious project is dedicated to developing and testing, as well as surveying and cataloguing, social innovations that will have a solid impact on improving the quality of life and well-being of older people. In particular the project aims to make a major contribution to the EU goal of extending healthy life years. It has four clear and achievable objectives that are intended to create a new paradigm in this field. These objectives directly address the present major barriers to innovation and to the achievement of the extension of healthy life years across the EU. The expert multi-disciplinary team is based on a highly successful existing collaboration, which will enable fast take-off and the guarantee of excellent team work. The work packages are designed to achieve impact in the public, private and third sectors. The project is built on the closest possible partnership with end users (or stakeholders) including older people themselves. It will deliver not only four new major social innovations in different EU countries (services models and products) but also a new European platform to promote knowledge exchange about and the sustainable implementation of social innovations to promote well-being in later life.

Keywords: ageing,social innovation,gerontology implementation,older people,well-being,quality of life,impact,knowledge exchange,sustainable intervention,best practice,healthy life expectancy,hle
A survey of the European cardiovascular research landscape and recommendations for future research strategy (CARDIOSCAPE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: France,United Kingdom
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2014-09-30
Duration (months): 23.0
Total project cost (EUR): 546164.8
EU funding (EUR): 487365.0
Participants: 2
Project status: CLOSED

CARDIOSCAPE will aim to outline the current CVD research and innovation landscape across Europe towards establishing the extent of duplication across national research programmes and the existence of gaps that reduce opportunities for innovation. It will build on and develop an existing comprehensive partner network, seeking to include actors covering the full innovation cycle, to help identify the most important research needs and approaches that will support more efficient valorisation of project results and better foster the transmission of new scientific findings into clinical practice. Project objectives include: • Survey research activities and funding for CV research, both public and private, at national and European level • Create CV research and funding database based on the survey results. • Summarise existing research and funding landscape for current state-of-the-art CV research • Assess and identify gaps, strengths and weaknesses and opportunities in European CV research by expert analysis • Develop and draft a final report to outline proposed recommendations and strategy for CV research in Europe. This report could serve as the basis for later post project development of more detailed research roadmaps, supporting the EC drive towards the Horizon 2020 CSF. • Disseminate effectively to the CV research community, the various stakeholders and the wider public the project results, relating to both the existing mapped research and funding landscape and the future recommendations for a more effective coordinated research approach. The development of recommendations for final report will be contingent on a wide ranging consultation not just within ESC but also externally, including actors and stakeholders from the pharmaceutical and medical device industries, SMEs, universities and medical research organisations, policy makers and hospitals and care organisations.

Keywords: cardiovascular disease survey european research landscape fragmentation coordination recommendations
Integrated health technology assessment for evaluating complex technologies (INTEGRATE-HTA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Germany,Netherlands,Norway,United Kingdom,Germany,Netherlands,Italy
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2013-01-01
End date: 2015-12-31
Duration (months): 36.0
Total project cost (EUR): 3893929.6
EU funding (EUR): 2975291.6
Participants: 7
Project status: CLOSED

The rise of complex, chronic diseases in an ageing European population led to the development of increasingly complex technologies. Current HTA is not well equipped to assess complex technologies due to a lack of attention to the diversity in patient characteristics and patient preferences, the limited consideration of context and implementation issues, and missing strategies to integrate all these aspects into a comprehensive assessment. We shall develop concepts and methods for HTA to enable a patient-centered, integrated assessment of the effectiveness, and the economic, social, cultural and ethical issues of complex technologies that takes context and implementation into account. We shall use palliative care for our case study as it is of extremely high relevance and it is an excellent example for a highly complex technology. More specifically, we shall adapt and develop methods and concepts - to assess the effectiveness and economic, social, cultural, and ethical issues of complex technologies, - to elicit patient preferences and patient-specific moderators of treatment - to include context, setting, and implementation - and, finally, to integrate these issues into a patient-centered, comprehensive assessment of complex technologies. Concepts and methods will be tested through assessing the complex technology “Specialist palliative care”. Revised guidance will be issued for comment to all relevant stakeholders. All partners of the consortium have an outstanding track record in the development of HTA methodology and are actively involved in major international initiatives in the field. The project will complement the work of similar initiatives and projects on HTA development, especially EUNetHTA/EUNetHTA JA and inform HTA agencies in all European countries. By focusing on an integrated assessment, we shall also match the need of policy-makers who prefer this to dealing with scattered information on innovative and complex technologies.

Keywords: health technology assessment,evaluation,complex interventions,palliative care,effectiveness,patient-orientation
Enhancing the (cost-)effectiveness of diabetes self-management education: A comparative assessment of different educational approaches and conditions for successful implementation (DIABETES LITERACY)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Belgium,Germany,Ireland,Austria,Netherlands,United Kingdom,United States,Israel,Taiwan, Province of China
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2015-12-31
Duration (months): 38.0
Total project cost (EUR): 3875206.2
EU funding (EUR): 2936244.0
Participants: 9
Project status: CLOSED

The project aims to contribute to building the evidence base to increase the effectiveness of diabetes self-management education in the EU Member States, as part of a comprehensive diabetes strategy at EU level. To that effect, it will perform a systematic and comparative content analysis of the national diabetes strategies and frameworks across the 27 EU MS, establish a compendium of diabetes self-management education programs in the MS, and assess the costs of diabetes education at present on a per person basis at a national level. To enhance the cost-effectiveness of diabetes treatment and care, it will assess and compare the effectiveness and cost-effectiveness of different methods for diabetes self-management education (individual and group education, IT based education, and self-help), assess the implementation fidelity of current diabetes self-management education programs, consider the moderating role of health literacy in self-management education for diabetic patients and develop and test literacy-appropriate diabetes education materials. It will also assess the conditions for effectiveness of self-management education programs in the way the health services are organised. The results will be used to inform policy decisions on improving the treatment and care for diabetic patients.

Keywords: diabetes,self-management education,cost-effectiveness evaluation,internet-based education,health literacy,implmentation fidelity
THALAssaemia MOdular Stratification System for personalized therapy of beta-thalassemia (THALAMOSS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Italy,Cyprus,Netherlands,Greece,United States,Czechia,Italy,United Kingdom,Israel
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2017-04-30
Duration (months): 54.0
Total project cost (EUR): 6730513.08
EU funding (EUR): 5020000.0
Participants: 14
Project status: CLOSED

THALAMOSS is aimed at development of universal sets of markers and techniques for stratification of β-thalassaemia patients into treatment subgroups for (a) onset and frequency of blood transfusions, (b) choice of iron chelation, (c) induction of fetal hemoglobin, (d) prospective efficacy of gene-therapy. At present, no framework exists to guide therapeutic decisions and personalised treatment of β-thalassaemia. THALAMOSS Workpackages: WP1. Recruitment, patient characterization and development of erythroid precursor cells cultures; WP2. Omics analyses; WP3. Novel therapeutic approaches; WP4. Data analysis; WP5. Dissemination and exploitation; WP6. Regulatory and ethical issues; WP7. Management. The impact of THALAMOSS is the provision of novel biomarkers for distinct treatment subgroups in β-thalassaemia (500-1000 samples from four European medical centres), identified by combined genomics, proteomics, transcriptomics and tissue culture assays, and establishment of routine techniques for detection of these markers. Translation of these activities into the product portfolio and R&D methodology of participating SMEs will be a major issue. THALAMOSS tools and technologies will (a) facilitate identification of novel diagnostic tests, drugs and treatments specific to patient subgroups and (b) guide conventional and novel therapeutical approaches for β-thalassaemia, including personalised medical treatments. Key researchers of THALAMOSS are R.Gambari (Ferrara University, Italy), M. Kleanthous (The Cyprus Foundation for Muscular Dystrophy Research, Cyprus), S.Philipsen (Erasmus Universitair Medisch Centrum Rotterdam, The Netherlands), E.Katsantoni (Biomedical Research Foundation, Academy of Athens, Greece), S.Rivella (Cornell University, NY, USA - The Children's Hospital of Philadelphia, Philadelphia, USA), P.Holub (Masaryk University, Czech Republic), P. Moi (Cagliari University, Italy), S. Menzel and SL.Thein (King’s College Hospital, UK), E.Voskaridou (Laiko General Hospital, Greece). Participating SMEs are Biocep (Israel), NovaMechanics Ltd. (Cyprus) and IRBM (Italy). Industrial activities are also provided by Harbour Antibodies (The Netherlands).

Keywords: beta-thalassaemia,genotyping,transcriptomics,proteomics,gene therapy,hbf induction,personalized therapy
Early warning signals of ageing in human stem cells and age-related disorders (SYSTEMAGE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Spain,Germany,Japan,United Kingdom,Singapore,Russian Federation,Germany
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2013-01-01
End date: 2017-12-31
Duration (months): 60.0
Total project cost (EUR): 7869114.41
EU funding (EUR): 5989925.0
Participants: 10
Project status: CLOSED

The regenerative power of a living organism is linked to the potential of its stem cells to replace the corresponding damaged tissue. Therefore organisms are as old as their stem cells. Whereas the vulnerability to cancer and chronic inflammation is associated with a decline of the immune system, the latter is in turn a sum product of interactions among hematopoietic stem cells (HSC), endothelial cells (EC) of the vascular systems and the microenvironment in the bone marrow, among others. Hence loss of regenerative function and propensity to contract cancers can be interpreted as harbingers of ageing at the level of somatic stem cells. Using HSC and their microenvironment as a model, our principal goal is to develop a systems-level understanding of the molecular mechanisms of ageing in somatic stem cells, the consequences, and means to correct these age-related alterations and diseases. We intend to apply integrative systems biology approaches to characterize the molecular players, genes and pathways that are associated with physiological processes of ageing and two age-related disorders, myelodysplastic syndromes (MDS) and B-cell chronic lymphocytic leukemia (B-CLL). We will use the resulting models of ageing to develop novel, molecular targeted strategies to treat age-related diseases. The SyStemAge consortium involves three hospital departments that are active in implementing innovative treatment strategies of leukaemia and MDS, a number of biomedical departments engaged with basic research in the processes underlying these diseases, two Systems Biology groups, one of Europe’s most experienced group in biomedical modelling and complex systems theory and two SMEs with proven expertise in the translation of biomedical models in novel therapy strategies in humans. SyStemAge is uniquely positioned to bridge the gap between the clinical, biomedical and natural sciences and immediately contribute to bio-gerontology.

Keywords: hematopoietic stem cell,myelodysplastic syndromes,b-cell chronic lymphocytic leukemia,chemoproteomics
Innovative Polymers for Energy Storage (IPES)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Materials and Synthesis
Countries involved: Spain
Call:  (ERC-2012-StG_20111012, 2012)
Start date: 2012-12-01
End date: 2018-11-30
Duration (months): 72.0
Total project cost (EUR): 1430239.0
EU funding (EUR): 1430239.0
Participants: 1
Project status: CLOSED

iPes project aims to provide adequate support to Dr. David Mecerreyes (DM) who is at the stage of consolidating an independent research team. During his scientific career, DM has demonstrated creative thinking and excellent capacity to carry out research and going beyond the state of the art. His meritorious record of research, scientific publications (128 ISI articles, h index = 33), project conception, private sector experience, networking ability (participated in 10 European collaborative projects) and capacity for supervising and coordinating a research team are presented in detail in the initial part of the proposal. He recently moved from the private sector to create a new research group at the University of the Basque Country. He is now in an excellent academic position and research environment to commit and be devoted to an ERC frontier research project. DM’s proposal passed to the second stage in the ERC starting grant call of last year. This year the research project has been re-built taking into account his group directions and the detected weak points of last year’s proposal. This is his last opportunity for participating to the ERC starting-grant call. iPes proposes an innovative research programme at the forefront of polymer chemistry. The proposal goes in depth into the topic of energetic polymers. iPes activities will fully develop the field of polymers for energy storage by using an innovative macromolecular engineering approach generating the ground for future innovations. The main S&T goal is to obtain new polymeric materials, to get an insight into their unique electronic properties, to model the new energetic polymers and to investigate their application in innovative battery prototypes. These technologies are currently dominated by inorganic electrode materials. iPes aims at bringing polymer chemistry to a next level and developing basic knowledge about innovative polymeric materials which may open up new opportunities for Energy Storage.

Keywords: macromolecular engineering,polymer architectures,block copolymers,self-assembling material,electroactive polymers,energetic polymers,conjugated polymers,plastic battery,nanodevices